drugset
drugset / Trial / NCT00346645

A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer

NCT00346645 ↗

Phase 2 Terminated 46 enrolled Gustave Roussy, Cancer Campus, Grand Paris
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Bortezomib is effective in the treatment of patients with non-small-cell lung cancer who have not received any prior chemotherapy regimen for advanced disease.

Timeline

Start
2006-06
Primary completion
2007-05
Completion
2007-12

Outcome

Outcome not reported

Stopped: “stopped after planned interim analysis for lack of efficacy”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — —

Indications

non-small cell lung carcinoma